On January 5, 2021, Sunco Bio-Pharmaceutical (Shanghai) Co., Ltd. was awarded the "(S)-1-tert-butoxycarbonyl-3-hydroxypiperidine" Shanghai high-tech achievement transformation project certification。

    As a national high-tech enterprise, Sunco Bio has always taken biotechnology to lead the development of the chemical pharmaceutical industry and bring human green and health as its mission. It has continuously increased its investment in scientific and technological research and development, and has made considerable progress and significant results in technological innovation and research and development. To expand the business in many ways, actively cooperate with well-known schools and enterprises at home and abroad, continuously develop its own development potential, optimize the internal configuration of the enterprise, and become better and stronger.

Project name: (S)-1-tert-Butoxycarbonyl-3-hydroxypiperidine

Item Number: 202010694

Item level: B

Whether it has independent intellectual property rights in the field of high-tech achievements:

Application: (S)-1-tert-butoxycarbonyl-3-hydroxypiperidine (CAS: 143900-44-1) is an important chiral intermediate for the synthesis of Ibrutinib API. Ibrutinib is used to treat lymphoma. It is a new anti-cancer drug that targets B-cell malignancies and was approved by the U.S. Food and Drug Administration (FDA) on November 13, 2013.

Definition of high-tech achievement transformation

    The transformation of high-tech achievements refers to the process by which enterprises transform high-tech into production and function. The state supports enterprises to implement the transformation of scientific and technological achievements through independent research and development, transfer of licenses, equity purchase, and industry-university-research cooperation. For high-tech achievement transformation projects reviewed and reported by enterprises, according to the completion of their comprehensive economic indicators and the attributes of the project’s intellectual property rights, the degree of innovation, etc., their R&D investment is related to the project’s intellectual property rights, invention patent certificates, or the substantive review stage Certificates of honor issued to enterprises after strict examination and thorough market investigation of invention patent application certification materials, utility model patent certificates, software copyright registration certificates, integrated circuit layout design registration certificates, etc.

Company Profile

    Sunco Bio-Pharmaceutical (Shanghai) Co., Ltd. was established in 2008 and is located in the International Medical Park, the southern area of Zhangjiang Hi-Tech Park in Pudong, Shanghai. It is a wholly-owned subsidiary of Zhejiang Sunco Bio-Pharmaceutical Co., Ltd. Sunco Bio is committed to the most cutting-edge research and development in the field of green pharmaceuticals, leading the development of the chemical pharmaceutical industry with green biotechnology, and providing novel products and high-quality services for the pharmaceutical industry. It is a high-tech enterprise in Shanghai and also in Shanghai. "Specialized, refined, special, new" enterprise.

     Sunco Bio's main business includes: the development and application of biological enzymes, the development and production of pharmaceutical intermediates, bulk drugs and functional chemicals. The company's main products are coenzyme series products, including NMN, NAD, NADP, NADH, NADPH, biological enzymes, pharmaceutical raw materials and intermediates. The company has customers and partners all over the world, and has formed close cooperative relationships with many pharmaceutical companies in North America, Europe, India and China.